ALX receptor ligands define a biochemical endotype for severe asthma

Isabell Ricklefs,1 Ioanna Barkas,1 Melody G. Duvall,1,2 Manuela Cernadas,1 Nicole L. Grossman,1 Elliot Israel,1 Eugene R. Bleecker,3 Mario Castro,4 Serpil C. Erzurum,5 John V. Fahy,6 Benjamin M. Gaston,5 Loren C. Denlinger,6 David T. Maugher,8 Sally E. Wenzel,10 Suzy A. Comhair,5 Andrea M. Coverstone,11 Merritt L. Fajt,10 Annette T. Hastie,3 Mats W. Johansson,12 Michael C. Peters,6 Brenda R. Phillips,3 Bruce D. Levy,1 and the National Heart Lung and Blood Institute’s Severe Asthma Research Program-3 Investigators13

1Pulmonary and Critical Care Medicine Division, Department of Medicine, Brigham and Women’s Hospital, and 2Division of Critical Care Medicine, Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. 3Center for Genomics and Personalized Medicine Research, School of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA. 4Division of Pulmonary and Critical Care Medicine, Departments of Medicine and Pediatrics, Washington University, St. Louis, Missouri, USA. 5Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA. 6Division of Pulmonary and Critical Care Medicine, Department of Medicine and the Cardiovascular Research Institute, UCSF, San Francisco, California, USA. 7Department of Pediatrics, Rainbow Babies and Children’s Hospital, Case Western Reserve University, Cleveland, Ohio, USA. 8Division of Allergy, Pulmonary, and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. 9Division of Statistics and Bioinformatics, Department of Public Health Sciences, Pennsylvania State University, Hershey, Pennsylvania, USA. 10Pulmonary, Allergy and Critical Care Medicine Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 11Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA. 12Department of Biomolecular Chemistry, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. 13The National Heart Lung and Blood Institute’s Severe Asthma Research Program-3 investigators are detailed in the supplemental acknowledgments.

BACKGROUND. In health, inflammation resolution is an active process governed by specialized proresolving mediators and receptors. ALX/FPR2 receptors (ALX) are targeted by both proresolving and proinflammatory ligands for opposing signaling events, suggesting pivotal roles for ALX in the fate of inflammatory responses. Here, we determined if ALX expression and ligands were linked to severe asthma (SA).

METHODS. ALX expression and levels of proresolving ligands (lipoxin A₄ [LXA₄], 15-epi-LXA₄, and annexin A1 [ANXA1]), and a proinflammatory ligand (serum amyloid A [SAA]) were measured in bronchoscopy samples collected in Severe Asthma Research Program-3 (SA [n = 69], non-SA [NSA, n = 47]) or healthy donors (HDs, n = 47).

RESULTS. Bronchoalveolar lavage (BAL) fluid LXA₄ and 15-epi-LXA₄ were decreased and SAA was increased in SA relative to NSA. BAL macrophage ALX expression was increased in SA. Subjects with LXA₄[SAA] levels had increased BAL neutrophils, more asthma symptoms, lower lung function, increased relative risk for asthma exacerbation, sinusitis, and gastroesophageal reflux disease, and were assigned more frequently to SA clinical clusters. SAA and aliquots of LXA₄[SAA] BAL fluid induced IL-8 production by lung epithelial cells expressing ALX receptors, which was inhibited by coincubation with 15-epi-LXA₄.

CONCLUSIONS. Together, these findings have established an association between select ALX receptor ligands and asthma severity that define a potentially new biochemical endotype for asthma and support a pivotal functional role for ALX signaling in the fate of lung inflammation.

TRIAL REGISTRATION. Severe Asthma Research Program-3 (SARP-3; ClinicalTrials.gov NCT01606826)
Introduction

Asthma is the most common disease of chronic lung inflammation, affecting nearly 1 in 13 Americans (1). The current clinical criteria for the diagnosis of asthma include a broad spectrum of patients with heterogeneous disease processes and distinct responses to medications (2). Approximately 10%–15% of asthmatic patients have severe asthma (SA) with daily symptoms and inadequate asthma control despite asthma-targeted controller medication use. These patients with SA have increased morbidity with significant adverse outcomes, including frequent outpatient visits, admissions to the hospital, and even life-threatening exacerbations (3). Cluster analyses utilizing patient clinical characteristics have identified at least 5 distinct clusters of asthmatic individuals (4, 5). Identifying disease mechanisms in asthma pathogenesis is critical to move the field from clinical phenotyping to molecular endotyping of patients to enable precision medicine approaches for improved asthma management (6). While type 2 “high” inflammation accounts for approximately 50% of asthma pathobiology (7), disease mechanisms for the remaining 50% of asthmatic subjects remain to be determined. A more detailed understanding of mechanisms underlying non–type 2 inflammation in asthma is needed.

In health, the resolution of inflammation is an active process governed by specific cellular events regulated by specialized proresolving mediators (SPMs) derived from essential fatty acids (8). Lipoxin A₄ (LXA₄) and 15-epi-LXA₄ are endogenous arachidonic acid–derived SPMs that potently regulate acute inflammation, yet are underproduced in many inflammatory diseases, including SA (9). Lipoxins and their stable analogs are protective in murine models of allergic lung inflammation, and display cell type–specific actions for human leukocytes to inhibit proinflammatory IL-13 production by group 2 innate lymphoid cells, halt granulocyte trafficking and activation, decrease T cell cytokine production, enhance natural killer cell functions, and stimulate macrophage CD206 expression and efferocytosis to resolve tissue inflammation (reviewed in ref. 9). Lipoxins also inhibit leukotriene-mediated prophlogistic actions, including in vivo in asthma (10), and decrease cytokine-induced human airway contractile responses (11). In peripheral blood, exhaled breath condensates, sputum, and bronchoalveolar lavage (BAL) fluid (BALF), LXA₄ levels are decreased in SA relative to non-SA (NSA) (12–15), suggesting a link between defective resolution mechanisms and persistent airway inflammation in some asthma patients.

LXA₄ and 15-epi-LXA₄ interact with specific receptors to exert their proresolving actions. Their high-affinity cognate receptors are ALX/FPR2 receptors (ALX) with a Kᵩ of approximately 1 nM (16). Of interest, ALX was the first receptor described to engage both lipid and peptide ligands (16), and subsequently several lipid and peptide ligands for ALX have been identified. Ligand recognition sites differ in the extracellular domains of ALX receptors and trigger distinct downstream events that dramatically change the signaling properties of the receptor depending on the engaging ligand (17). In sharp contrast to LXA₄’s counter-regulatory signaling, SAA engages the same ALX receptors to promote inflammation (18, 19). SAA is generated as an acute-phase protein in COPD exacerbations in amounts that are 2–3 log orders higher than LXA₄ that overwhelms SPM signaling via ALX (18). Another ALX ligand of potential interest in SA is annexin A1 (ANXA1), a corticosteroid-inducible protein that can interact with ALX receptors to transduce proresolving actions similar to LXA₄ (20). Of interest, when apparently healthy individuals are challenged with a skin irritant, they segregate into fast and slow resolvers of the dermal wound based on lipoxin production and expression of ALX receptors (21). Thus, relative levels of these lipid and peptide ALX ligands could serve as a rheostat for inflammatory host responses in airway disease, as lipoxins can allosterically inhibit SAA interactions with ALX (18). Together, the relative abundance and actions of these proinflammatory versus proresolving ALX ligands may biochemically regulate airway phlogistic tone and contribute to unresolved inflammation in SA.

Here, we analyzed BALF samples collected from subjects participating in the National Heart, Lung and Blood Institute’s Severe Asthma Research Program-3 (SARP-3) and have identified a potentially new asthma biochemical endotype related to levels of the ALX receptor ligands LXA₄ and SAA that was associated with neutrophilic inflammation, increased asthma symptoms, and decreased lung function in SA.
Results

Subject characteristics. Subjects with SA and NSA, and nonasthmatic healthy donors (HD) were recruited to participate in SARP-3 at 7 research centers across the United States. Relative to NSA, subjects with SA had increased symptoms as manifested by lower Asthma Control Test (ACT) and higher Asthma Control Questionnaire (ACQ) scores. Spirometric measures of lung function were lower in SA than NSA and HD despite the SA cohort’s use of more asthma-targeted medications (Table 1). A subset of subjects agreed to bronchoscopy with BAL as part of their baseline phenotyping. SA subjects had more lung inflammation with increased BAL neutrophils (Table 1).

SA subjects have decreased lipoxins and increased SAA and macrophage ALX receptor expression. The fate of innate inflammatory responses is dictated in part by ALX receptor signaling (16, 21), so the presence of BALF ALX ligands with proinflammatory (i.e., SAA) or proresolving properties (i.e., LXA4, 15-epi-LXA4, and ANXA1) and BAL cell surface ALX receptor expression were determined. SA subjects had significantly less BALF LXA4 (median 0.23 pg/μg protein, mean 0.28 pg/μg protein) and 15-epi-LXA4 (median 1.02 pg/μg protein, mean 1.24 pg/μg protein) than NSA subjects (LXA4: median 0.32 pg/μg protein, mean 0.40 pg/μg protein; 15-epi-LXA4: median 1.47 pg/μg protein, mean 1.88 pg/μg protein) (Figure 1, A and B).

Table 1. Clinical characteristics and bronchoalveolar lavage leukocytes for subjects undergoing bronchoscopy

<table>
<thead>
<tr>
<th></th>
<th>Healthy Donors (HD)</th>
<th>Nonsevere Asthma (NSA)</th>
<th>Severe Asthma (SA)</th>
<th>NSA vs. SA</th>
<th>HD vs. NSA</th>
<th>HD vs. SA</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of subjects</td>
<td>47</td>
<td>51</td>
<td>69</td>
<td>ns</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>Clinical data</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>40.1 ± 12.9 (20–62)</td>
<td>36.9 ± 12.4 (18–61)</td>
<td>42.4 ± 13.6 (14–67)</td>
<td>ns</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>% Male</td>
<td>19 (40%)</td>
<td>17 (33%)</td>
<td>24 (35%)</td>
<td>ns</td>
<td>ns</td>
<td></td>
</tr>
<tr>
<td>% African American</td>
<td>11 (23%)</td>
<td>14 (27%)</td>
<td>22 (32%)</td>
<td>ns</td>
<td>ns</td>
<td></td>
</tr>
<tr>
<td>% White</td>
<td>31 (66%)</td>
<td>37 (74%)</td>
<td>45 (65%)</td>
<td>ns</td>
<td>ns</td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>27.6 ± 5.7 (20–44)</td>
<td>30.0 ± 9.2 (18–61)</td>
<td>31.4 ± 8.2 (19–67)</td>
<td>ns</td>
<td>ns</td>
<td>C</td>
</tr>
<tr>
<td>Symptom control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% Uncontrolleda</td>
<td>n.a.</td>
<td>32 (63%)</td>
<td>68 (98%)</td>
<td>D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACQ</td>
<td>n.a.</td>
<td>1.08 ± 0.9 (0–3)</td>
<td>1.93 ± 1.1 (0–5)</td>
<td>D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACT</td>
<td>n.a.</td>
<td>19.61 ± 4.0 (7–25)</td>
<td>14.48 ± 4.5 (5–23)</td>
<td>D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung function</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 % predicted</td>
<td>102.4 ± 12.5 (78.46–139.2)</td>
<td>89.8 ± 16.3 (42–124)</td>
<td>75.0 ± 19.1 (35–116)</td>
<td>D</td>
<td>E</td>
<td>D</td>
</tr>
<tr>
<td>FVC % predicted</td>
<td>104.7 ± 14.2 (84.12–137.2)</td>
<td>102.6 ± 17.2 (64–145)</td>
<td>89.4 ± 17.6 (52–133)</td>
<td>D</td>
<td>ns</td>
<td>D</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td>97.7 ± 5.6 (85.4–109.6)</td>
<td>87.5 ± 9.0 (61–109)</td>
<td>82.8 ± 9.0 (62–106)</td>
<td>C</td>
<td>D</td>
<td>D</td>
</tr>
<tr>
<td>Medications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhaled corticosteroids</td>
<td>0 (0%)</td>
<td>35 (69%)</td>
<td>67 (97%)</td>
<td>D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High dose of inhaled corticosteroids</td>
<td>0 (0%)</td>
<td>4 (8%)</td>
<td>66 (96%)</td>
<td>D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral steroids</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>16 (23%)</td>
<td>D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-acting β agonists</td>
<td>0 (0%)</td>
<td>21 (37%)</td>
<td>64 (93%)</td>
<td>D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-acting anticholinergic medication</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>3 (4%) P = 0.13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukotriene receptor antagonists</td>
<td>0 (0%)</td>
<td>11 (22%)</td>
<td>24 (35%)</td>
<td>P = 0.12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omalizumab</td>
<td>0 (0%)</td>
<td>1 (2%)</td>
<td>8 (13%)</td>
<td>C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BAL leukocyte differentials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cell count (millions)</td>
<td>4.9 ± 4.6 (0–25)</td>
<td>4.0 ± 2.7 (0–12)</td>
<td>6.4 ± 13.2 (0–107)</td>
<td>ns</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>Macrophages (%)</td>
<td>91.7 ± 5.8 (73–99)</td>
<td>92.2 ± 5.1 (79–99)</td>
<td>87.7 ± 10.1 (53–99)</td>
<td>E</td>
<td>ns</td>
<td>C</td>
</tr>
<tr>
<td>Neutrophils (%)</td>
<td>1.6 ± 1.9 (0–10)</td>
<td>1.4 ± 1.4 (0–7)</td>
<td>3.3 ± 4.9 (0–24)</td>
<td>E</td>
<td>ns</td>
<td>C</td>
</tr>
<tr>
<td>Eosinophils (%)</td>
<td>0.3 ± 0.4 (0–2)</td>
<td>1.1 ± 2.8 (0–17)</td>
<td>1.8 ± 5.0 (0–35)</td>
<td>ns</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>Lymphocytes (%)</td>
<td>6.5 ± 5.0 (0–22)</td>
<td>5.3 ± 4.5 (0–19)</td>
<td>7.3 ± 5.9 (0–34)</td>
<td>ns</td>
<td>ns</td>
<td>ns</td>
</tr>
</tbody>
</table>

aValues represent the mean ± SD (range). bUncontrolled symptoms were defined as the occurrence of one of the following: 2 or more steroid bursts, hospitalization, intensive care unit admission, use of a ventilator, FEV1 % predicted less than 80%, ACT less than 20, or self-reported worsening with tapering steroids. BMI, body mass index; ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; n.a., not applicable. \( ^{1} P < 0.05, ^{2} P < 0.001, ^{3} P < 0.01, ^{4} P < 0.001, ^{5} NS < 0.05 \). Comparison between 3 groups was performed by 1-way ANOVA followed by Tukey’s test to adjust for multiple comparisons and \( ^{\chi^{2}} \) test. Comparison between 2 groups was performed by Student’s t test.
BALF lipoxins were significantly increased in NSA relative to HD, without significant differences between SA and HD cohorts (Figure 1, A and B), consistent with the findings in an earlier SARP cohort (14). No significant differences in immunoreactive ANXA1 levels were identified between the cohorts (Figure 1C). In contrast, SAA levels were increased in SA (median 3.03 pg/μg protein, mean 11.35 pg/μg protein) relative to NSA (median 0 pg/μg protein, mean 11.21 pg/μg protein) (Figure 1D). Of note, BALF SAA levels were below the limit of detection in 51 of the 120 asthma subjects and these samples were arbitrarily assigned a value of 0 pg/μg protein for analysis. Differences in BALF ALX ligand levels were also present when BALF was not corrected for protein (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.93534DS1). BAL macrophage surface ALX receptor expression was determined by flow cytometry, with data expressed as a normalized index for ALX (median fluorescence intensity [MFI] of ALX divided by MFI of isotype control) (see Methods). A stepwise increase in the BAL macrophage ALX index from HD to NSA to SA was detected (Figure 1E).

ALX ligands differentially correlate with asthma inflammation, symptoms, and lung function. To screen for relationships between the BALF ALX ligand levels and asthma clinical parameters, a Pearson correlation matrix was constructed using measures of disease activity from all asthma subjects (NSA and SA; n = 120) (Figure 2). LXA₄ levels correlated positively with 15-epi-LXA₄ and inversely with SAA. The ALX ligands were also compared to clinical parameters of lung inflammation, asthma symptoms, and measures of lung function. Notably, the percentage of BALF neutrophils was inversely correlated with LXA₄ and 15-epi-LXA₄ and positively correlated with SAA. As expected, the ACQ and ACT scores were inversely correlated and significantly related to lung function. BALF levels of LXA₄ were inversely correlated with asthma symptoms (i.e., high ACQ, low ACT scores). LXA₄ and 15-epi-LXA₄ were also positively associated with lung function. SAA was not significantly related to asthma symptoms or lung function parameters. There were no significant correlations between BALF ALX ligand levels and fractional exhaled nitric oxide (FeNO), methacholine PC 20 (provocation challenge causing a 20% fall in forced expiratory volume in 1 second [FEV₁]), or lung function reversibility with albuterol. Because of limited sample size, this analysis was not corrected for multiple comparison testing, yet it strongly suggested relationships between select ALX ligands and major characteristics of clinical asthma, namely lung inflammation, asthma symptoms, and lung function.

BALF neutrophilia in SA is associated with decreased LXA₄ and increased SAA levels. BALF leukocyte subsets were determined in NSA and SA subjects and HD. As expected, macrophages were the most numerous BAL cell type accounting for 88%–92% of BAL leukocytes (Figure 3A). SA subjects had significantly higher percentages of BAL neutrophils than NSA subjects (mean ± SEM 3.32% ± 0.59% SA versus 1.38% ± 0.19% NSA; Figure 3B). There were also trends for increased BAL lymphocytes and eosinophils in SA relative to NSA and HD.
HD (Figure 3, C and D). BALF LXA₄ levels inversely correlated with BAL neutrophil percentage in the total asthma cohort or when the SA cohort was analyzed independently (Figure 3, E and F). In contrast, SAA levels were positively correlated with BAL neutrophil percentage in the complete asthma cohort as well as when SA was analyzed separately (Figure 3, G and H). LXA₄ levels were also positively correlated with lung function (i.e., FEV₁ and forced vital capacity [FVC] [percentage predicted values]), but there was no correlation between SAA levels and lung function in this cohort (Supplemental Figure 2).

ALX receptor ligands and expression are associated with asthma symptoms. To further investigate relationships between the ALX signaling pathway and measures of asthma symptoms, the continuous variables for BALF ALX ligands were converted to categorical high and low subgroups using the median value to define a cutoff between the subgroups. Using the median BALF SAA value (1.22 pg/μg protein; Figure 4A), the relationships between SAA₁ to SAA₄ subjects and measures of asthma symptoms were determined. Subjects defined as SAA₁ to SAA₄ had significantly increased ACQ and decreased ACT scores relative to SAA₄ to SAA₄ subjects (Figure 4B), consistent with increased asthma symptoms in the SAA₁ to SAA₄ group. When stratified by asthma severity, there were more NSA subjects that were SAA₄ and more SA subjects that were SAA₁ (Figure 4C). ACQ scores were significantly different between SAA₄ and SAA₄ subjects when considering only those subjects with SA (Figure 4D). Of note, significant differences between the SAA₁ and SAA₄ cohorts for ACQ and ACT scores were not apparent in the NSA cohort (Supplemental Figure 3A).

Because BALF LXA₄ levels were inversely related to SAA levels and asthma symptoms by Pearson correlation (Figure 2), the difference between LXA₁ to LXA₄ groups of subjects and asthma symptoms was determined. The median LXA₄ level was used as a cutoff between groups (0.23 pg/μg protein; Figure 4E). LXA₁ to LXA₄ subjects had higher ACQ scores and significantly lower ACT scores compared with LXA₁ to LXA₄ subjects, consistent with more symptoms in the LXA₁ to LXA₄ group (Figure 4F). When stratified by severity, NSA subjects were more numerous in the LXA₁ to LXA₄ group and approximately 70% of the LXA₁ to LXA₄ cohort were subjects with SA (Figure 4G). In contrast to our findings with SAA, the low LXA₄ levels were not significantly related to symptom scores in the SA cohort (Figure 4H); however, among NSA subjects, the LXA₁ to LXA₄ group did have significantly fewer symptoms as evidenced by higher ACT scores (Supplemental Figure 3B). Of note, administration of a single dose of intramuscular triamcinolone did not result in discernible changes in either LXA₁ or SAA levels after 3 to 6 weeks in either SA or NSA subjects (Supplemental Figure 4).

With opposing relationships for asthma symptoms for the ALX ligands SAA and LXA₄, we next performed similar analyses for the BAL macrophage ALX index. Asthma subjects were categorized into ALX₁ to ALX₄ cohorts using the median ALX index to define the cutoff between subgroups (median 4.61; Figure 4I). ALX₁ to ALX₄ asthma subjects had higher ACQ scores and significantly lower ACT scores, consistent with increased asthma symptoms (Figure 4J). After stratification by asthma severity (Figure 4K), ALX₁ to ALX₄ subjects had significantly increased symptoms by both measures (i.e., ACQ and ACT) in the SA cohort (Figure 4L). The ALX index was not significantly linked to symptom score in the NSA cohort (Supplemental Figure 3C). Of added interest, the BAL macrophage ALX index correlated with macrophage indices of MHC class 2 and CD206 expression in asthma subjects (Supplemental Figure 5).
SAA and LXA\textsubscript{4} levels together represent a biochemical endotype that distinguishes SA from NSA. Individually, SAA and LXA\textsubscript{4} levels were both associated with asthma severity. More SA subjects had SAA\textsubscript{hi} and LXA\textsubscript{4}lo levels and more NSA subjects had SAAlo and LXA\textsubscript{4}hi levels (Figure 4). In SA, macrophage ALX expression was increased (Figure 1) and associated with increased asthma symptoms (Figure 4), so we next determined if BALF levels for the combination of the ALX ligands was linked to SA. Asthma subjects were divided into 4 groups based on BALF LXA\textsubscript{4} and SAA levels (Figure 5A). The approach of categorical grouping of high and low (based on median values) was chosen because the relationship between an individual’s BALF LXA\textsubscript{4} and SAA levels suggested that these ALX ligands were independently regulated (Figure 5A). When subjects were stratified by clinical severity, it was striking that more than half of NSA but fewer than a quarter of SA were LXA\textsubscript{4}hiSAAlo (beige, Figure 5B). In contrast, 41% of SA subjects were LXA\textsubscript{4}loSAAhi compared with 22% of NSA subjects (purple, Figure 5B). Of note, for asthmatic subjects, the relative ratio of BALF SAA to LXA\textsubscript{4} levels was strongly correlated with BAL neutrophilia (Figure 5C), more so than the level of either ALX ligand independently (Figure 3, E and G). When comparing asthmatic subjects in these 2 distinct groups, the LXA\textsubscript{4}loSAA\textsubscript{hi} group had significantly higher BAL neutrophils and asthma symptoms (i.e., higher ACQ, lower ACT) and lower lung function (i.e., percentage predicted FEV\textsubscript{1} and FVC) than the LXA\textsubscript{4}hiSAA\textsubscript{lo} group (Figure 5, D–F). The total BAL white blood cell count and percentage of lymphocytes and eosinophils did not differ between the 2 groups (Supplemental Figure 6, A–C). The percentage of subjects with an ACQ score greater than 1.5 was higher in the LXA\textsubscript{4}loSAA\textsubscript{hi} cohort (Supplemental Figure 6D), representing another measure of the increased symptoms in this group.

Cluster analyses from SARP-1 used clinical parameters to identify 5 asthma subtypes (mild allergic asthma, mild-moderate allergic asthma, more severe older-onset asthma, severe variable allergic asthma, and severe fixed-airflow asthma) (5). Using this classification here with SAA and LXA\textsubscript{4} as biochemical markers of ALX receptor signaling, it was notable that 71% of the LXA\textsubscript{4}loSAA\textsubscript{hi} group were assigned to one of the NSA clusters and 64% of the LXA\textsubscript{4}loSAA\textsubscript{hi} subjects were assigned to one of the SA clusters (Figure 5G and Supplemental Figure 6E).
SAA is an acute-phase protein, and with the relationship for the LXA\textsubscript{4}^{-}SAA\textsuperscript{hi} endotype to asthma severity and neutrophilic lung inflammation, we next determined if there was a relationship for LXA\textsubscript{4} and SAA to exacerbations and common asthma comorbidities. Both high SAA and low LXA\textsubscript{4} levels were significantly related to sinusitis, gastroesophageal reflux disease (GERD), and obesity (BMI > 30), and low LXA\textsubscript{4} was also related to history of more frequent acute exacerbation over the prior year (Table 2). Together, the combination of low LXA\textsubscript{4} levels and high SAA levels (i.e., the LXA\textsubscript{4}^{-}SAA\textsuperscript{hi} endotype) was even more closely associated with these asthma comorbidities (Table 2).

SAA and 15-epi-LXA\textsubscript{4} signaling via ALX receptors regulates production of the neutrophil chemoattractant IL-8. To determine the functional relationship for these ALX receptor ligands, we next turned to an ALX-dependent in vitro reporter assay that we have previously qualified in chronic obstructive pulmonary disease (18). A549 lung epithelial cells were stably transfected to express the human ALX/FPR2 receptor (hALX). BALF samples were selected from HD, NSA, and SA subjects with representative levels of ALX ligands (Figure 6A). SAA gave a concentration-dependent (0–10 ng/ml) increase in IL-8 production by A549hALX cells (Figure 6B). When the A549hALX cells were exposed to BALF (see Methods), several of the representative SA BALFs substantially increased IL-8 production (Figure 6C), reflective of the relative amounts of BALF SAA and LXA\textsubscript{4}. The addition of exogenous 15-epi-LXA\textsubscript{4} inhibited A549hALX cell IL-8 production by cells conditioned with BALF (Figure 6D). Of note, maximal inhibition of IL-8 production by 15-epi-LXA\textsubscript{4} was for A549hALX cells that had been conditioned with BALF from LXA\textsubscript{4}^{-}SAA\textsuperscript{hi} subjects (Figure 6D).

**Discussion**

Here, in SARP-3, we measured the abundance of 4 ligands for ALX receptors, namely LXA\textsubscript{4}, 15-epi-LXA\textsubscript{4}, ANXA1, and SAA, with the potential for opposing effects on asthmatic airway responses. In SA, BAL macrophage ALX receptor expression was increased and BALF ligands for ALX were selectively regulated. BALF levels of proresolving lipoxins were decreased and levels of proinflammatory SAA were increased in SA. Levels of lipoxins inversely correlated to SAA, BAL neutrophils, and asthma symptoms, and lipoxins were positively correlated to measures of lung function. SAA\textsuperscript{hi} and ALX\textsuperscript{hi} subjects more commonly had SA with increased ACQ and decreased ACT scores. When LXA\textsubscript{4} and SAA levels were considered together in a combined endotype, a stronger association with asthma symptoms, lung function, and airway neutrophilia was noted than when either mediator was considered individually. LXA\textsubscript{4}^{-}SAA\textsuperscript{hi} subjects had more lung inflammation and asthma symptoms and lower lung function relative to LXA\textsubscript{4}^{-}SAA\textsuperscript{lo} subjects. LXA\textsubscript{4}^{-}SAA\textsuperscript{hi} and LXA\textsubscript{4}^{-}SAA\textsuperscript{lo} subjects segregated to SA and NSA clinical clusters, respectively. Importantly, LXA\textsubscript{4}^{-}SAA\textsuperscript{hi} subjects had significantly increased likelihood for asthma exacerbation in the past year and for the asthma comorbidities of sinusitis, GERD, and obesity. Exposure to SAA or BALF from SA subjects increased production of the neutrophil chemoattractant IL-8 by ALX-expressing human

---

**Table 2. Asthma exacerbations and comorbidities are associated with high SAA and low LXA\textsubscript{4}**

<table>
<thead>
<tr>
<th></th>
<th>SAA\textsuperscript{hi} (n = 60)</th>
<th>SAA\textsuperscript{lo} (n = 60)</th>
<th>P value (\textsuperscript{2})</th>
<th>P value (\textsuperscript{2} with Bonferroni correction)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;1 AE</td>
<td>21 (35%)</td>
<td>24 (40%)</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>12 (20%)</td>
<td>24 (40%)</td>
<td>0.01</td>
<td>0.04</td>
</tr>
<tr>
<td>GERD</td>
<td>18 (30%)</td>
<td>28 (47%)</td>
<td>0.04</td>
<td>ns</td>
</tr>
<tr>
<td>BMI &gt; 30</td>
<td>19 (32%)</td>
<td>32 (53%)</td>
<td>0.01</td>
<td>0.04</td>
</tr>
<tr>
<td>LXA\textsubscript{4} (n = 60)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;1 AE</td>
<td>29 (48%)</td>
<td>16 (27%)</td>
<td>0.01</td>
<td>0.04</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>24 (40%)</td>
<td>12 (20%)</td>
<td>0.02</td>
<td>ns</td>
</tr>
<tr>
<td>GERD</td>
<td>29 (48%)</td>
<td>17 (28%)</td>
<td>0.01</td>
<td>0.04</td>
</tr>
<tr>
<td>BMI &gt; 30</td>
<td>34 (57%)</td>
<td>17 (28%)</td>
<td>0.002</td>
<td>0.008</td>
</tr>
<tr>
<td>SAA\textsuperscript{lo}LXA\textsubscript{4} (n = 40)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;1 AE</td>
<td>10 (25%)</td>
<td>18 (46%)</td>
<td>&lt;0.05</td>
<td>ns</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>6 (15%)</td>
<td>18 (46%)</td>
<td>0.003</td>
<td>0.01</td>
</tr>
<tr>
<td>GERD</td>
<td>11 (28%)</td>
<td>22 (56%)</td>
<td>0.009</td>
<td>0.04</td>
</tr>
<tr>
<td>BMI &gt; 30</td>
<td>11 (41%)</td>
<td>26 (74%)</td>
<td>&lt;0.001</td>
<td>&lt;0.005</td>
</tr>
</tbody>
</table>

\*Results are expressed as number of patients (percentage). SAA, serum amyloid A; LXA\textsubscript{4}, lipoxin A\textsubscript{4}; AE, acute exacerbation; GERD, gastroesophageal reflux; BMI, body mass index; ns, not significant
lung epithelial cells in vitro. This SAA-driven IL-8 production by epithelial cells was mitigated by exposure to 15-epi-LXA₄ at pharmacological doses, supporting a functional interaction between the ALX ligands relevant to the neutrophilic inflammation in SA. Together, these findings support a mechanistic role for ALX receptor signaling by SAA and LXA₄ in lung inflammation in SA that defines a potentially new biochemical endotype for patient stratification in asthma.

ALX receptors are intriguing targets for regulating the fate of inflammatory responses. LXA₄ and SAA interact with ALX receptors to exert opposing effects on inflammation (18). ALX receptors are 7-membrane-spanning, G protein–coupled receptors that are present on several lung cell types relevant to asthma pathogenesis, including neutrophils (22), eosinophils (23), group 2 innate lymphoid cells (24), natural killer cells (24), lymphocytes (25), monocytes (26), dendritic cells (27, 28), macrophages (29), and airway structural cells (30). LXA₄ is a high-affinity ligand for ALX that signals for antiinflammatory and proresolving cellular responses (16). SAA binds with lower affinity, yet this acute-phase reactant is substantially more abundant than LXA₄ during infection and the upstroke of acute inflammation (18). Also relevant in SA patients with comorbidities, corticosteroids can enhance SAA production, especially in conjunction with

Figure 4. SAA and macrophage ALX expression are associated with increased symptoms in severe asthma. Asthma subjects were categorized into subgroups based on low or high BALF levels of SAA (A–D), LXA₄ (E–H), and macrophage ALX expression (I–L). The median value for each variable was used to define the cutoff between the low and high subgroups (SAA cutoff = 1.22 pg/µg protein, LXA₄ cutoff = 0.25 pg/µg protein, ALX index cutoff = 4.6 pg/µg protein). Cutoff values are delineated by the gray vertical line. A histogram shows the distribution of subjects based on BALF (A) SAA level, (E) LXA₄ level, and (I) BAL macrophage ALX index. (B, F, and J) Validated measures of asthma symptoms (ACQ and ACT scores) were compared between low (open diamonds) and high (closed diamonds) subgroups for SAA, LXA₄, and ALX index. (C, G, and K) The distributions of SAA, LXA₄, and ALX index among NSA (blue) and SA (red) subjects are shown in violin plots. (D, H, and L) ACQ and ACT scores were compared in SA subjects for low (open triangles) and high (closed triangles) subgroups for SAA, LXA₄, and ALX index. Scatter plots show individual subject data with mean ± SEM. n = 51 NSA and n = 69 SA subjects.*P < 0.05, **P < 0.01 by Mann-Whitney test or 2-tailed Student’s t test. BALF, bronchoalveolar lavage fluid; SAA, serum amyloid A; ACQ, asthma control questionnaire; ACT, asthma control test; NSA, nonsevere asthma; SA, severe asthma; LXA₄, lipoxin A₄; ALX, airway lipoxin A₄ receptor.
LPS (18). Distinct from LXA₄’s interaction with the seventh transmembrane domain and adjacent regions (31, 32), SAA interacts with the first and second extracellular loop domains (33), resulting in a marked shift in receptor conformation and dimerization that changes the receptor’s proresolving signaling to proinflammatory signaling (17). Here in SA, ALX expression was increased on BAL macrophages and associated with increased asthma symptoms. Macrophage ALX expression correlated with surface CD206 expression, which marks M2 macrophages that participate in endogenous pathways of inflammation resolution (34, 35). Together with the increased SAA and decreased lipoxins in SA BALF, the increase in ALX expression on BAL macrophages likely reflects SAA-driven outcomes, including the increased lung inflammation (i.e., BAL neutrophilia) despite higher doses of corticosteroids. With the presence of SAA and LXA₄ in proximity to ALX receptors in the lung and their divergent influences on inflammatory responses, ALX receptors are poised to serve as a pivotal signaling nexus for acute inflammation or its resolution.

Lipoxins are products of arachidonic acid metabolism that are structurally and functionally distinct from leukotrienes and prostaglandins. LXA₄ was first detected in humans in BALF from patients with lung disease, including asthma (36). Lipoxins are the lead members of a new genus of endogenous chemical
signals, SPMs, which are partially defined by their ability to inhibit granulocyte recruitment and activation in inflamed tissues as well as to promote macrophage-mediated clearance of dead cells, microbes, and debris in catabasis (8). Distinct from increased leukotriene production by some asthmatic patients, lipoxin levels are decreased in uncontrolled asthma and SA (13). Current anti-leukotriene drugs would not be expected to increase lipoxins in asthma. There are likely multiple factors responsible for the defective lipoxin production in SA; however, the increased oxidative stress in SA airways was recently determined to be a major cause of reduced lipoxin generation (11). In human studies, inhaled LXA$_4$ dampens bronchoprovocation in asthma (10) and lipoxins regulate cytokine-mediated increases in bronchial constriction induced by methacholine, histamine, and thromboxane (11). Recently, a stable LXA$_4$ analog was shown to markedly decrease allergic inflammation and symptoms in patients with juvenile eczema (37). Preclinical studies have established that LXA$_4$ analogs that resist metabolic inactivation can prevent and potently reduce allergen-driven airway hyperresponsiveness to methacholine, airway mucus metaplasia, and type 2 inflammation (38, 39). Transgenic expression of hALX receptors also leads to decreased inflammatory responses to allergens, supporting a role for endogenous ALX ligands in antiinflammation and proresolution (23). In addition to ALX, lipoxins can interact with additional receptors, including cysLT1 — the pharmacological target of one of the classes of anti-leukotriene drugs (40). Together, these findings point to pivotal proresolving roles for lipoxins in health to control airway phlogistic responses and promote their resolution. Here, the diminished BALF levels of lipoxins in SA would be predicted from prior publications to disable a major endogenous regulatory pathway for airway inflammation, mucus, and hyperreactivity, and our results show a strong and consistent correlation between low LXA$_4$ and increased lung inflammation, asthma symptoms, and comorbidities, and lower lung function in SA.

In contrast to lipoxins, there are several peptide ligands for ALX receptors that engage these receptors to promote inflammatory responses. The acute-phase reactant SAA is one of the ALX peptide ligands and can induce neutrophil chemotaxis and activation via ALX (41, 42). SAA is increased in severe allergic asthma (43) and can prevent dendritic cell apoptosis to induce glucocorticoid resistance in CD4$^+$ T cells (44). Here, BALF SAA levels were increased in SA and strongly associated with BAL neutrophils. SAA$^{hi}$ subjects had increased asthma symptoms and a higher relative risk of sinusitis, GERD, and obesity. If subjects had both low LXA$_4$ levels and high SAA levels (i.e., LXA$_4^{lo}$SAA$^{hi}$) then their relative risk for BAL neutrophils, asthma symptoms, and lower lung function were all increased. Recently, some subjects with SA with non–type 2 inflammation were identified as IL-6$^{hi}$ (45). IL-6 induces SAA expression (46) and may

![Figure 6. SAA and 15-epi-LXA$_4$ signaling via ALX receptors regulates production of the neutrophil chemoattractant IL-8.](image-url)
conspire with this acute-phase protein to activate neutrophils and non–type 2 lung inflammation in SA, in particular in those with systemic metabolic alterations associated with obesity. In A549ALX epithelial cells, BALF from LXA4SAA subjects increased production of the neutrophil chemoattractant IL-8, which was inhibitable by 15-epi-LXA4. At ALX receptors, 15-epi-LXA4 inhibition of SAA is allosteric in nature (18), and when given at pharmacological doses, 15-epi-LXA4 can decrease SAA-driven IL-8 production by human airway epithelial cells in vitro and SAA-mediated acute inflammation in vivo in mice (18). Of interest for SA, SAA production is increased by corticosteroids and its expression is synergistically increased by the combination of steroids and LPS (18). Additional soluble mediators acting via distinct or synergistic pathways with SAA also are likely to contribute to epithelial cell IL-8 production and neutrophil chemotraction in SA. Subjects enrolled in SARP-3 were clinically characterized before and after intramuscular triamcinolone and adult subjects with SA continued to manifest lower FEV1 and worse asthma control as compared with NSA after the systemic corticosteroids (47). Of note, BALF levels of LXA4, 15-epi-LXA4, and SAA were not significantly altered by a single dose of intramuscular triamcinolone when measured 3 to 6 weeks after steroid administration. Unlike 15-epi-LXA4, corticosteroids do not inhibit SAA-mediated lung inflammation (18), suggesting that for some subjects with SA their chronic neutrophilic lung inflammation could be perpetuated by corticosteroids and that SAA levels could inform more precise asthma management by helping to identify subjects at risk for this unintended consequence of corticosteroids.

Biochemical analyses here have linked ALX receptor signaling to the pathophysiology of SA. Using clinical and statistical approaches, 5 phenotypes of adult asthma have been defined (5), but there remains a need to connect these phenotypes to distinct molecular mechanisms for SA pathogenesis (6). We chose a candidate pathway approach based on preclinical evidence that linked ALX signaling to SA, and BAL LXA4 and SAA levels segregated subjects into discrete clinical clusters, suggesting that this biochemical pathway could convey additional value for patient stratification as an asthma endotype. Findings here suggest that these ALX ligands should be included in future studies designed to comprehensively model genetic, metabolic, and environmental influences and clinical characteristics for patient endotyping in SA.

Here, we have identified significant associations for BALF LXA4SAA levels with neutrophilic lung inflammation and poorly controlled asthma; however, there are several potential limitations to consider. While it was advantageous for biochemical analyses to have a relatively large number of BAL samples from this carefully phenotyped group of asthma subjects, it would not be practical to routinely perform bronchoscopy in a clinical (or clinical trial) setting. It will be important in future studies to obtain and analyze respiratory samples collected by less invasive means (i.e., sputum, exhaled breath condensate) to determine the influence of anatomic compartment on the relationships uncovered here with bronchoscopy specimens. The cross-sectional nature of the analyses here does not address the stability of this endotype, a question best addressed with samples obtained by less invasive means. Regarding additional ALX ligands, the ELISA used here for ANXA1 does not distinguish between intact and cleaved protein, so the absence of a relationship here does not preclude its potential existence when more specific experimental tools become available. There are also several additional peptide and lipid ligands for ALX receptors that might further enhance the discriminatory power of ALX signaling for identification of asthma endotypes.

In summary, ALX receptor expression was increased in asthmatic BAL macrophages and we have identified a cassette of ALX receptor ligands that are selectively regulated in BALF in asthma. Levels of lipoxins and SAA correlated with lung inflammation and clinical parameters of asthma control. In particular, subjects with LXA4SAA BALF were more likely to have SA with increased BAL neutrophils, asthma symptoms, and asthma comorbidities, and decreased lung function. At pharmacological levels, 15-epi-LXA4 functionally opposed SAA signaling at ALX receptors to inhibit production of the neutrophil chemoattractant IL-8. BALF LXA4SAA subjects were assigned to discrete clinical clusters from LXA4SAA subjects, suggesting that these biochemical mediators could identify subgroups of asthma subjects and serve as a new asthma biochemical endotype for non–type 2, steroid resistant inflammation in SA.

Methods

Study design. SARP-3 is an NHLBI-funded study designed to characterize molecular, cellular, and physiological phenotypes in subjects with SA and NSA (ClinicalTrials.gov NCT01606826). Asthmatic and healthy subjects were recruited and completed baseline characterization with some subjects agreeing to bronchoscopy. Details regarding SARP methods, subject enrollment, and study procedures can be found in Peters et al. (45).
Participants and sample collection. Subjects 13 years of age and older with asthma and healthy control subjects were recruited between November 2012 and February 2015 by 7 geographically dispersed research centers in the USA. European Respiratory Society/American Thoracic Society guidelines were used to categorize subjects as SA or NSA (48). Control subjects were individuals who reported general health and were nonsmokers with no history of lung disease, atopic disease, or allergic rhinitis. BAL was performed with three 50-ml aliquots of warm saline, and BALF was recovered by hand suction. Subjects received intramuscular triamcinolone (1 mg/kg up to a maximum dose of 40 mg) and some subjects agreed to undergo a second bronchoscopy 3 to 6 weeks later and BAL samples were collected in the same manner. BAL cells were enumerated and differential leukocyte counts determined. Cell-free BALF supernatant was divided into several aliquots. One aliquot of BALF (1 ml) was directly mixed with iced methanol (2 ml, for 1:2, vol/vol) before storing at –80°C. The other aliquots were directly stored at –80°C. The stored aliquots were later shipped to Brigham and Women’s Hospital for analyses.

Lipid extraction. Aliquots of BALF with methanol (1:2, vol/vol) were brought to dryness in vacuo using a BUCHI Rotavapor R-200/205. The samples were resuspended with methanol (500 μl) and distilled/deionized water (10 ml) followed by extraction using C18 SepPak cartridges (Waters) as previously described (13). The methyl formate fraction was brought to dryness under a gentle stream of nitrogen and each sample was resuspended in 1 ml of methanol and stored at –80°C until LXA₄ and 15-epi-LXA₄ ELISAs were performed.

Protein assay. The Pierce BCA Protein Assay Kit (Thermo Fisher) was used for BALF protein determination. Samples with less than 25 μg of protein were excluded from further analysis (n = 3; 1 NSA, 2 SA).

ELISA. LXA₄ and 15-epi-LXA₄ levels in the BALF were measured by ELISA (Neogen). Extracted BALF samples stored in methanol were brought to dryness under a gentle stream of nitrogen and resuspended in ELISA buffer. SAA and ANXA1 levels were measured by ELISA (commercial kits from Abazyme and Cloud-Clone, respectively) in aliquots of BALF stored in the absence of methanol. LXA₄, 15-epi-LXA₄, SAA, and ANXA1 levels were normalized to the total protein content of the BALF. Some subjects had an SAA level below the limit of detection and these samples were assigned a value of 0 pg/μg for analysis. The median values for LXA₄ and SAA were used to segregate subjects into high and low subgroups.

Flow cytometry. BAL cell pellets were available from a subgroup of subjects. For ex vivo staining, BALF cells were blocked with mouse serum (Sigma-Aldrich) in PBS for 30 minutes at 4°C. The cells were then incubated with Viability Dye eFluorR660 (eBioscience) as per the manufacturer’s instructions followed by 30 minutes of incubation with the following antibodies against human proteins: anti-ALX-PerCP (clone 304405, R&D Systems); anti–HLA-DR (MHC class II)-allophycocyanin-Cy7 (APC-Cy7) (clone L243, BD Biosciences); and anti-CD206 (macrophage mannose receptor)-phycoerythrin (PE) (clone 19.2, eBioscience) or with directly conjugated unrelated antibodies of the same isotype (BD Biosciences) at 4°C. Data were acquired on a Canto II flow cytometer (Becton Dickinson) and analyzed using FlowJo software version 10.1 (Tree Star). Macrophages were identified as single cells (by doublet exclusion), viable (Viability Dye eFluorR660 negative), CD206⁺ cells. The MFI of ALX, MHC class II, and CD206 were assessed and normalized with the MFI of the isotype control antibody (MFI cell surface marker/MFI isotype control = MFI index).

In vitro A549 cell culture. A549 cells transfected to stably express the human ALX receptor were used (as in ref. 18). A549hALX cells were seeded into a 48-well plate (5 × 10⁴ cells/well) and cultured in RPMI 1640 (Lonza) supplemented with 2 mM L-glutamine, 10% heat-inactivated fetal calf serum (Gibco), penicillin (100 IU/ml), and streptomycin (100 μg/ml) at 37°C in 5% CO₂ until confluent. When confluent, A549hALX cells were cultured with serum-free media for 16 hours and then exposed to BALF (100 μl) and serum-free RPMI media (100 μl, 1:1 vol/vol) for 24 hours (37°C, 5% CO₂). In select experiments, recombinant human SAA (0–10 ng/ml, Peprotech), 15-epi-LXA₄ (100 nM, Cayman Chemical), or vehicle control was added. At the end of the incubations, supernatants were collected on ice and stored at −80°C. IL-8 levels in the supernatants were measured by ELISA (R&D Systems). If there was no increase in IL-8 production after exposure to BALF, the samples were assigned a value of zero (Figure 6C).

Statistics. In figures, data are expressed either individually with indication of the median value or as mean ± SEM; in tables, data are expressed as mean ± SD. For violin plots in Figure 4, bin sizes and widths were determined for each variable automatically in SPSS based on the underlying data distribution. Statistical significance of differences was assessed by 2-tailed Student’s t test, 1-way ANOVA, Kruskal-Wallis test (when normality assumptions were not met), or χ² test as noted using SPSS version 23.0 (IBM). Post hoc Tukey’s test (for ANOVA analyses) and Dunn’s test (for Kruskal-Wallis analyses) were used to correct for multiple comparisons. Correlations were evaluated by Pearson’s correlation coefficient (r) and linear...
or nonlinear (for graphs with log axes) regression lines are shown. Correlation analyses included samples with a value of 0 for statistical analysis, but data points with a value of 0 were excluded for regression line analyses of detectable ALX ligands. A P value less than 0.05 was considered significant and the reported P values were adjusted for multiple comparisons.

Study approval. Written informed consent was obtained after institutional review board approval at each of the seven sites.

Author contributions
IR, IB, M. Cernadas, and MGD designed and performed experiments, analyzed data, and wrote the manuscript. NLG, EI, ERB, M. Castro, SCE, JVF, BMG, LCD, DTM, SEW, SAC, AMC, MLF, ATH, MWJ, MCP, and BRP collected specimens, analyzed data, and wrote the manuscript. BDL conceived of the study, designed experiments, analyzed data, and wrote the manuscript. All authors contributed to the editing of the final manuscript. All authors agreed to all of the content of the submitted manuscript.

Acknowledgments
The authors thank the study participants, the SARP-3 investigators and clinical research coordinators, and the data-coordinating center. See supplemental Acknowledgments for SARP-3 consortium details. We also thank Guangli Zhu for her expert technical assistance. This study was conducted with the support of grants that were awarded by the NHLBI as follows: Elliot Israel and Bruce Levy, Harvard Medical School U10 HL109172; Eugene Bleecker, Wake Forest University U10 HL109164; Mario Castro, Washington University U10 HL109257; Serpel Erzurum, Cleveland Clinic (Co-PI, Virginia-Cleveland Consortium) U10 HL109250; John Fahy, UCSF U10 HL109146; Benjamin Gaston, Case Western Reserve University U10 HL109250; Nizar Jarjour, University of Wisconsin U10 HL109168; Sally Wenzel, University of Pittsburgh U10 HL109152; David Mauger, Penn State University U10 HL109086-04; the work was also supported in part by R01-HL122531 (BDL), a fellowship from the German Society for Pediatric Pneumology (IR), and K12-HD047349 (MGD). In addition, this program is supported through the following NIH National Center for Advancing Translational Sciences (NCATS) awards: UL1 TR001420 to Wake Forest University, UL1 TR000427 to the University of Wisconsin, UL1 TR001102 to Harvard University, and UL1 TR000454 to Emory University. See supplemental acknowledgments for the NHLBI SARP-3 investigators' details. The interests of Bruce Levy were reviewed and are managed by the Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict-of-interest policies.

Address correspondence to: Bruce Levy, 75 Francis Street, Boston, Massachusetts, 02115, USA. Phone: 617.525.5407; Email: b Levy@partners.org.